BRIEF published on 06/09/2026 at 22:05, 4 months 22 days ago Update on Inventiva's Share Capital and Voting Rights as of May 2026 Euronext Paris Share Capital Voting Rights Biopharmaceutical Inventiva
PRESS RELEASE published on 06/09/2026 at 22:00, 4 months 22 days ago Statement of Total Voting Rights and Shares Forming The Company’s Share Capital as of May 22, 2026 Inventiva reports total voting rights and shares forming the company's share capital as of May 22, 2026, in compliance with Article R. 22-10-23 of the French Commercial Code Euronext Paris Shares Total Voting Rights Inventiva MASH
BRIEF published on 06/08/2026 at 09:41, 4 months 23 days ago Sofinnova's threshold crossing in INVENTIVA Voting Rights Threshold Crossing New Actions Inventiva Sofinnova Partners
BRIEF published on 06/02/2026 at 14:35, 4 months 29 days ago Inventiva Resumes Trading on Euronext Paris Euronext Paris Debt Financing Trading Resumption Inventiva MASH Treatment
PRESS RELEASE published on 06/02/2026 at 14:30, 4 months 29 days ago Inventiva Announces Trading Resumption of its Ordinary Shares on Euronext Paris Inventiva announces trading resumption of its ordinary shares on Euronext Paris following Debt Financing Transaction and ADS Offering Euronext Paris Ordinary Shares Clinical-Stage Biopharmaceutical Trading Resumption Inventiva
BRIEF published on 06/02/2026 at 07:35, 4 months 29 days ago Temporary suspension of Inventiva shares on Euronext Paris Euronext Paris Funding Nasdaq Inventiva Temporary Suspension
BRIEF published on 06/02/2026 at 07:35, 4 months 29 days ago Inventiva Halts Trading of Ordinary Shares on Euronext Paris Euronext Paris Trading Halt Inventiva MASH Treatment Nadsaq
PRESS RELEASE published on 06/02/2026 at 07:30, 4 months 29 days ago Inventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris Inventiva announces temporary trading halt of its ordinary shares on Euronext Paris for a proposed financing transaction. Trading to resume after communication Euronext Paris Trading Halt Clinical Trial Inventiva Metabolic Dysfunction
BRIEF published on 05/26/2026 at 22:05, 5 months 6 days ago Inventiva Announces its First Quarter 2026 Financial Results Financial Results Treasury Biopharmaceutical Inventiva NATiV3
PRESS RELEASE published on 05/26/2026 at 22:00, 5 months 6 days ago Inventiva Reports 2026 First Quarter Financial Information¹ Inventiva reports first quarter 2026 financial information, with cash and cash equivalents at €75.0 million and short-term deposits at €121.5 million. Explore company's financial results and upcoming milestones Financial Information Inventiva NATiV3 Cash Equivalents Short-term Deposits
Published on 10/30/2026 at 23:35, 2 days 4 hours ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 2 days 4 hours ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 19:00, 2 days 9 hours ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 2 days 12 hours ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 11/01/2026 at 10:35, 17 hours 42 minutes ago Shenzhen Unveils APEC China 2026 Host-City Theme Song and Music Video
Published on 11/01/2026 at 05:00, 23 hours 17 minutes ago 2026 Yangtze River Culture Festival Opens in Yonglian Village, Zhangjiagang, Jiangsu
Published on 10/31/2026 at 16:35, 1 day 11 hours ago SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand
Published on 10/30/2026 at 22:49, 2 days 5 hours ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 23:00, 2 days 5 hours ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 18:00, 2 days 10 hours ago 2026 half-year earnings & third quarter revenue
Published on 10/30/2026 at 12:00, 2 days 16 hours ago Capital increase through exercise of subscription rights
